A Study to Investigate the Presence of Malignant Cells in Seminal Fluid During Radical Prostatectomy


About this study

The purpose of this study is to investigate whether malignant prostate cancer cells can be identified in seminal fluid expressed during the course of robotic radical prostatectomy, as such cells may be a currently unrecognized source of local recurrence after surgery.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients (aged 18 and older).
  • Undergoing robotic radical prostatectomy for adenocarcinoma of the prostate, Gleason grade group 2-5.

Exclusion Criteria: 

  • Age < 18.
  • Clinical N+ or M+ disease.
  • Clinical T4 disease.
  • Prior hormone therapy or prostate radiation therapy.
  • Small cell carcinoma.
  • Planned open radical prostatectomy.
  • Gleason grade group 1.


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Igor Frank, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer